Evidence map›Paper›PMID 20146584›Full record

ReviewFuture oncology (London, England)2010

WWOX gene and gene product: tumor suppression through specific protein interactions.

Zaidoun Salah, Rami Aqeilan, Kay Huebner

Open access · greenAbstract readReview
In one paragraph

Review in Future oncology (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Cancers · 2021
    Article
  17. Review
  18. Article
  19. Article
  20. Fragile GeneFrontiers in oncology · 2021
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Zaidoun SalahThe Lautenberg Center for Immunology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Pharmacy Building, Jerusalem 91120, Israel. zaidouns@ekmd.huji.ac.il
Rami Aqeilan
Kay Huebner
Hebrew University of Jerusalem · ILThe Ohio State University · US

Funding

Wwox as a Critical Signal Mediator in Breast CancerR01CA120516 · NCI · OHIO STATE UNIVERSITY · PI HUEBNER, KAY · 2006 to 2013
$1.3M
Fhit modulation of cell cycle progression and DNA damage responseR01CA132453 · NCI · OHIO STATE UNIVERSITY · PI HUEBNER, KAY · 2007 to 2010
$1.3M
NCI NIH HHS R01 CA120516NCI NIH HHS R01 CA132453
6 · The paper itself

Abstract

The WWOX gene, an archetypal fragile gene, encompasses a chromosomal fragile site at 16q23.2, and encodes the approximately 46-kDa Wwox protein, with WW domains that interact with a growing list of interesting proteins. If the function of a protein is defined by the company it keeps, then Wwox is involved in numerous important signal pathways for bone and germ-cell development, cellular and animal growth and death, transcriptional control and suppression of cancer development. Because alterations to genes at fragile sites are exquisitely sensitive to replication stress-induced DNA damage, there has been an ongoing scientific discussion questioning whether such gene expression alterations provide a selective advantage for clonal expansion of neoplastic cells, and a parallel discussion on why important genes would be present at sites that are susceptible to inactivation. We offer some answers through a description of known WWOX functions.

Indexed as

Chromosome Fragile SitesHumansNeoplasmsOxidoreductasesSignal TransductionTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseOxidoreductasesTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseWWOX protein, human

Identifiers

PMID20146584
PMCPMC2832309
OpenAlexW2166732297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.